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1. Introduction
DNA damage appears to be a fundamental problem for life [1]. As we show below, the average
human cell receives about 60,000 DNA damages per day due to natural endogenous causes.
Most DNA damages are repaired by one or more enzyme systems. However, excessive DNA
damages are a major primary cause of cancer. Error-prone replication past DNA damages or
inaccurate repair of DNA damages give rise to mutations and epimutations that, by a process
of natural selection, can cause progression to cancer.
DNA damage is a change in the basic structure of DNA that is not itself replicated when the
DNA is replicated. A DNA damage can be a chemical addition or disruption to a base of DNA
(creating an abnormal nucleotide or nucleotide fragment) or a break in one or both strands of
DNA. When DNA carrying a damaged base is replicated, an incorrect base may be inserted
opposite the site of the damaged base in the complementary strand, and this can become a
mutation in the next round of replication. Also DNA double-strand breaks may be repaired
by an inaccurate end-joining process leading to mutations. In addition, a double strand break
can cause rearrangements of the chromosome structure (possibly disrupting a gene, or causing
a gene to come under abnormal regulatory control), and, if such a change can be passed to
successive cell generations, it is also a form of mutation. Mutations, however, can be avoided
if accurate DNA repair systems recognize DNA damages as abnormal structures, and repair
the damages prior to replication.
DNA damages occur in both replicating, proliferative cells (e.g. those forming the internal
lining of the colon or blood forming “hematopoietic” cells), and in differentiated, non-dividing
cells (e.g. neurons in the brain or myocytes in muscle). Cancers occur primarily in proliferative
tissues. If DNA damages in proliferating cells are not accurately repaired due to inadequate
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expression of a DNA repair gene, the risk of cancer increases. In contrast, when DNA damages
occur in non-proliferating cells and are not repaired due to inadequate expression of a DNA
repair gene, the damages can accumulate and may cause premature aging [1].
A mutation is a change in the DNA sequence in which normal base pairs are substituted, added,
deleted or rearranged. The DNA containing a mutation still consists of a sequence of standard
base pairs, and the altered DNA sequence can be copied when the DNA is replicated. A
mutation can prevent a gene from carrying out its function, or it can cause a gene to be
translated into a protein that functions abnormally. Mutations can activate oncogenes,
inactivate tumor suppressor genes or cause genomic instability in replicating cells, and an
assemblage of such mutations, together in the same cell, can lead to cancer. Cancers usually
arise as a consequence of mutations conferring a selective advantage that leads to clonal
expansion. Colon cancers, for example, have an average of 3 or 4 “driver” mutations (mutations
occurring repeatedly in different colon cancers) and about 75 “passenger” mutations (muta‐
tions occurring infrequently in colon cancers) [2]. Colon cancers also have an average of 17
focal amplifications, 28 recurrent deletions and up to 10 translocations [3]. Since mutations
have a normal DNA structure, they cannot be recognized or removed by DNA repair processes
in living cells. Removal of a mutation only occurs if it is sufficiently deleterious to cause the
death of the cell.
An epigenetic change (epimutation) is a heritable change in gene expression that is not
accompanied by a change in DNA sequence. These epigenetic changes can include DNA
methylation, constitutive (not facultative or induced) changes in small noncoding RNAs
including microRNAs, altered chromatin architecture, histone tail modifications by methyla‐
tions and acetylations that repress or activate transcription of the DNA wrapped around the
histones, and nucleosome re-positioning [4]. These epigenetic changes are very frequent in
cancers. For instance, 24 colon cancers were analyzed at more than 3,000 DNA segments within
the genome for differentially methylated regions (DMRs). The colon cancers were found to
have between 515 and 33,576 DMRs compared to adjacent histologically normal tissues [5].
Most of the differential methylations were increases in methylation, though some were
hypomethylations. Increased methylation of the promoter region of a gene generally represses
the transcription of that gene. Another epigenetic factor, a microRNA (miRNA), can have
several hundred “target genes” [6]. Those target genes are repressed by the miRNA causing
the degradation or blocked translation of the messenger RNA produced by those genes.
Increased expression of an miRNA can occur due to epigenetic hypomethylation of the
promoter region controlling transcription of the miRNA. When 754 miRNAs were evaluated
in progression to esophageal adenocarcinoma (EAC), the expression levels of about 130
miRNAs were increased and the expression levels of 16 miRNAs were decreased in tissues
with EAC (or in tissues with Barrett’s esophagus, a precursor lesion) compared to histologically
normal esophageal tissues adjacent to the EACs [7].
As described in detail below, inherited germ-line mutations of DNA repair genes give rise to
syndromes characterized by increased risk of cancer. Such inherited mutational defects of
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DNA repair genes can allow excess unrepaired DNA damages to accumulate in somatic cells.
Inaccurate translesion synthesis past the unrepaired DNA damages can cause mutations. In
addition, error prone DNA repair pathways, such as non-homologous end joining, can also
cause mutation. Erroneous or incomplete DNA repair may also cause epigenetic modifications.
Thus, deficient DNA repair that leaves behind excess DNA damages can cause increased
mutations and epimutations, and these mutations and epimutations can include both the
driver mutations and the epigenetic alterations central to progression to cancer.
As will be described below, whole genome sequencing of many different types of cancers show
that between thousands to hundreds of thousands of mutations occur in various types of
cancers. Mutation frequencies in non-cancerous tissues are substantially lower. Loss-of-
function mutations in DNA repair genes are relatively infrequent in sporadic (non-germ-line
induced) cancers. However, DNA repair genes frequently express reduced levels of repair
proteins in cancers due to epigenetic repression, and this can lead to increased DNA damage,
and hence, increased mutation. The epigenetic repression of DNA repair gene expression is
also frequent in the field defects that surround and give rise to cancers. Thus, epigenetic
reduction of DNA repair appears to be a frequent early step, central to progression to cancer.
2. Inherited mutations in DNA repair genes and cancer syndromes
Hereditary cancer syndromes account for about 5% to 10% of the incidence of cancers [8]. Two
reviews list 48 [8] and 55 [9] familial cancer susceptibility syndromes. Mutations in 38 genes
related to DNA repair cause hereditary cancer syndromes (Table 1). Since such syndromes are
frequently caused by mutations in DNA repair genes, this indicates that sporadic reductions
in DNA repair gene expression may also be a frequent and crucial early event in progression
to sporadic cancer.
3. Mutations versus epimutations in DNA repair genes during progression
to cancer
Upon reviewing the results from sequencing 3,284 tumors and the 294,881 mutations found in
these tumors, Vogelstein et al. [10] noted that germ-line mutations that give rise to cancer are
infrequent in sporadic tumors. This indicates that if an early step in progression to sporadic
cancer (rather than a germ-line syndrome) is reduction in function of a DNA repair gene, the
reduction is likely due to an epigenetic alteration in that gene (an epimutation), rather than to
a mutation (change in base pair-sequence).
Two examples are given here. In one case, for 113 sequential colorectal cancers, only four had
a missense mutation in the DNA repair gene O-6-methylguanine-DNA methyltransferase
(MGMT), while the majority had reduced MGMT expression due to methylation of the MGMT
promoter region (an epigenetic alteration) [11]. Five reports presented evidence that between
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40% and 90% of colorectal cancers have reduced MGMT expression due to methylation of the
MGMT promoter region [12-16].
Similarly, out of 119 cases of mismatch repair-deficient colorectal cancers that lacked DNA
repair gene PMS2 expression, PMS2 was deficient in 6 due to mutations in the PMS2 gene,
while in 103 cases PMS2 expression was deficient because its pairing partner MLH1 was
repressed due to promoter methylation (PMS2 protein is unstable in the absence of MLH1)
[17]. In the other 10 cases, loss of PMS2 expression was likely due to epigenetic over-expression
of the miRNA, miR-155, which down-regulates MLH1 [18].
4. DNA damages are very frequent
As shown in Table 2, an average of more than 60,000 endogenous DNA damages occur per
cell per day in humans. These are largely caused by exposure to reactive oxygen molecules,
hydrolytic reactions, and interactions with other reactive metabolites (including lipid peroxi‐
dation products, endogenous alkylating agents and reactive carbonyl species) [19].
In addition to the damages shown in Table 2, further DNA damages occur due to environ‐
mental assaults. Doll and Peto [20], compared cancer rates of specific organs in humans in the
United States to cancer rates in these organs in other countries. They concluded that 75 - 80%
of the cases of cancer in the United States were likely avoidable, and were due to DNA
damaging agents found in occupational, medical and “social” exposures (including diet and
tobacco).
Colon cancer is an example of a diet-related cancer that appears to be caused by excessive
exposure of the colon to DNA damaging agents, mainly bile acids. Bile acids are released into
the intestinal tract in response to consumption of fatty foods to aid in their digestion. As
reviewed by Bernstein et al. [21], 14 published reports indicate that the secondary bile acids
deoxycholic acid and lithocholic acid cause DNA damage. The concentration of these bile acids
in the colon are affected by diet and are doubled in the colonic contents of humans on typical
diets in the United States who were experimentally fed a high fat diet [22]. The potential
consequences of high fecal bile acid concentrations is illustrated by the following comparison.
The concentration of deoxycholic acid (DOC) in the feces of Native Africans in South Africa is
7.30 nmol/g wet weight stool while that of African Americans is 37.51 nmol/g wet weight stool,
so that there is 5.14 fold higher concentration of DOC in stools of African Americans than in
Native Africans [23]. Native Africans in South Africa have a colon cancer rate of <1:100,000 [24]
compared to the incidence rate for male African Americans of 72:100,000 [25], a more than 72-
fold difference in rates of colon cancer. In populations migrating from low-incidence to high-
incidence countries cancer rates change rapidly, and within one generation may reach the rate
in the high-incidence country. This has been observed, for instance, in the colon cancer
incidence of migrants from Japan to Hawaii [26]. These changes in colon cancer rates among
migrants are thought to be largely due to changes in diet.
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DNA repair gene(s) Encodedprotein Repair pathway(s) affected* Cancers with increased risk
breast cancer 1 & 2 BRCA1BRCA2
HRR of double-strand breaks and
daughter strand gaps [27] Breast, Ovarian [28]
ataxia telangiectasia mutated ATM
Different mutations in ATM reduce
HRR, single-strand annealing
(SSA), NHEJ or homology directed
double- strand break rejoining
(HDR) [29]
Leukemia, Lymphoma, Breast
[29,30]
Nijmegen breakage syndrome NBS NHEJ [31] Lymphoid cancers [31]
meiotic recombination 11 MRE11 HRR and NHEJ [32] Breast [33]
Bloom’s Syndrome (helicase) BLM HRR [34]
Leukemia, Lymphoma, Colon,
Breast, Skin, Lung,
Auditory canal, Tongue,
Esophagus, Stomach,
Tonsil, Larynx, Uterus [35]
Werner Syndrome (helicase) WRN HRR, NHEJ, long patch BER [36]
Soft tissue sarcoma,
Colorectal, Skin, Thyroid,
Pancreatic [37]
Rothman Thomson syndrome
Rapadilino syndrome
Baller Gerold syndrome
RECQ4 Helicase likely active in HRR [38]
Basal cell carcinoma,
Squamous cell carcinoma,
Intraepidemial carcinoma [39]
Fanconi’s anemia gene FANC
A,B,C,D1,D2,E,F,G,I,J,L,M,N FANCA etc. HRR and TLS [40]
Leukemia, Liver tumors,
Solid tumors many areas [41]
xeroderma pigmentosum
C, E [DNA damage binding
protein 2 (DDB2)]
XPC
XPE
Global genomic NER repairs
damage in both transcribed and
untranscribed DNA [42,43]
Skin cancer (melanoma and non-
melanoma) [42,43]
xeroderma pigmentosum
A, B, D, F, G
XPA XPB
XPD XPF
XPG
Transcription coupled NER repairs
the transcribed strands of
transcriptionally active genes [44]
Skin cancer (melanoma and non-
melanoma) [44]
xeroderma pigmentosum V (also
called polymerase H)
XPV
(POLH) Translesion Synthesis (TLS) [45]
Skin cancers (basal cell, squamous
cell, melanoma) [45]
mutS (E. coli) homolog 2
mutS (E. coli) homolog 6
mutL (E. coli) homolog 1
postmeiotic segregation
increased 2 (S. cereviciae)
MSH2 MSH6
MLH1 PMS2 MMR [46] Colorectal, Endometrial [46]
mutY homolog (E. coli) MUTYH BER of A mispaired with8-OHdG [47] Colon [47]
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DNA repair gene(s) Encodedprotein Repair pathway(s) affected* Cancers with increased risk
ataxia telaniectasia and RAD3
related ATR
DNA damage response
likely affects HRR, but not NHEJ
[48]
Oropharyngeal cancer [49]
Li Fraumeni syndrome P53 HRR, BER, NER and DDR for thoseand NHEJ and MMR [50]
Sarcoma, Breast, Osteo-sarcoma,
Brain, Adreno-cortical carcinomas
[51]
Severe combined immune
deficiency (SCID)
Artemis
DCLRE1C NHEJ [52] B-cell lymphoma [53]
CHEK2 (a DDR gene) CHEK2 Double-strand breaks [54] Breast, Ovarian [55]
*HRR, homologous recombinational repair; NHEJ, non-homologous end joining; BER, base excision repair; TLS,
translesion synthesis; MMR, mismatch repair; DDR, DNA damage response
Table 1. Inherited mutations in genes related to DNA repair that increase the risk of cancer
The likely role of bile acids as causative agents in colon cancer is illustrated by experiments
with mice. When mice were fed a diet supplemented with the bile acid deoxycholate (DOC)
for 10 months, raising their colonic level of DOC to that of humans on a high fat diet, 45% to
56% of these mice developed colon cancers, while mice fed the standard diet alone, with 1/10
the level of colonic DOC, developed no colon cancers [56,57].
DNA damages Reported rate of occurrence
Oxidative 86,000 per cell per day in rats
10,000 per cell per day in humans [58]
Depurinations 9,000 per cell per day [59]
Depyrimidations 696 per cell per day [60]
Single-strand breaks 55,000 per cell per day [60]
Double-strand breaks ~50 per cell cycle in humans [61]
O6-methylguanine 3,120 per cell per day [60]
Cytosine deamination 192 per cell per day [60]
Table 2. DNA damages due to natural endogenous causes in mammalian cells
5. DNA repair deficiency allows excess DNA damage accumulation
At least 169 enzymes are either directly employed in DNA repair or influence DNA repair
processes [62]. Of these, 139 are directly employed in DNA repair processes including base
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excision repair (BER), nucleotide excision repair (NER), homologous recombinational repair
(HRR), non-homologous end joining (NHEJ), mismatch repair (MMR) and direct reversal of
lesions (DR). The other 30 enzymes are employed in the DNA damage response (DDR) needed
to initiate DNA repair; chromatin structure modification required for repair; reactions needed
for the reversible, covalent attachment of ubiquitin and small ubiquitin-like modifier (SUMO)
proteins to DDR factors that facilitate DNA repair; or modulation of nucleotide pools.
When the incidence of endogenous and exogenous DNA damages is high, decreases in
expression of DNA repair genes or DNA damage response (DDR) genes would be expected
to lead to a build-up of DNA damage within a cell. Five examples below indicate that a DNA
repair deficiency leads to excess DNA damage accumulation.
BLM deficiency. As reviewed by Manthei and Keck [63] and Croteau et al. [64], Bloom's
syndrome helicase (BLM) likely has roles in multiple steps in homologous recombinational
repair (HRR) of double-strand breaks (DSBs) in DNA. BLM is able to stimulate nuclease activity
in a 5′ end resection at a DSB. This aids in initiation of HRR. This activity may serve to shuttle
DSBs away from non-homologous end joining (NHEJ) pathways, which are more error prone.
In the second step of HRR, the RAD51 recombinase forms a helical filament on the free 3′ DNA
end. A homology search within double-stranded DNA by the RAD51/ssDNA complex produces
a D-loop structure as a result of invasion of a ssDNA segment into a homologous sister-
chromatid or chromosome. In this step, BLM interacts with RAD51 and is able to migrate and
unwind D-loops. BLM is also part of a “dissolvasome” that resolves Holiday junctions during
HRR. Humans with a germ-line BLM mutation accumulate chromosomal rearrangements and
aneuploidy [35] and have increased susceptibility to several kinds of cancer (Table 1).
MUTYH deficiency. MUTYH protein is a glycosylase that removes an undamaged adenine
mispaired with the damaged DNA base 8-OH-deoxyguanine. This removal leaves an apurinic/
apyrimidinic (AP) site that initiates a special long-patch base excision repair. This repair
depends on accurate translesion synthesis by polymerase lambda (pairing a cytosine opposite
the 8-OH-deoxyguanine), creating a cytosine:8-OH-deoxyguanine pair, which then allows
other enzymes to recognize and remove the 8-OH-deoxyguanine [47]. If MUTYH (or MYH)
expression is decreased by short hairpin RNA (shRNA) (that makes a tight hairpin turn that
can silence target gene expression) in human-origin HeLa cells, external application of H2O2
causes increased accumulation of 8-OH-deoxyguanine [65]. This finding shows that deficient
expression of DNA repair protein MUTYH allows 8-OH-deoxyguanine accumulation when
cells are under oxidative stress. Note that a germ-line MUTYH mutation increases the risk of
colon cancer (Table 1).
ATM deficiency. In response to double-strand breaks, both ATM and ATR phosphorylate a
multitude of protein substrates, including p53, and the checkpoint kinases, CHEK1 and
CHEK2. These phosphorylated substrates promote cell cycle arrest and initiate DNA repair.
Arresting the cell cycle allows time for enzymes to repair the DNA before DNA synthesis or
chromosome segregation initiates [66,67]. As shown by Flockerzi et al. [68] and Rübe et al. [69],
when DNA repair is reduced by homozygous loss of function of ATM, a low dose of radiation
causes more DNA damage, especially double-strand breaks, to accumulate than when ATM
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is wild-type. Note that germ-line ATM mutations increase the risk of leukemia, lymphoma and
breast cancer (Table 1).
ERCC1 deficiency. Nucleotide excision repair (NER) removes helix-distorting “blocking”
lesions located throughout the genome. Such lesions may block movement of DNA polymerase
during DNA replication or a lesion on the transcribed strand may block elongating RNA
polymerase movement within an active gene. XPC-RAD23B initiates the repair response by
recognizing a damage-induced structural change in DNA and then binds to the strand opposite
the lesion and not the chemical adduct itself. After a number of steps, the two endonucleases,
XPF-ERCC1 and XPG then carry out incisions 5’ and 3’, respectively, to the DNA damage. The
presence of genetic polymorphisms of ERCC1, with reduced DNA repair capacity, allow more
benzo[a]pyrene-DNA adducts to accumulate in cells exposed to benzo[a]pyrene [70]. Thus,
bulky helix-distorting lesions accumulate when ERCC1 protein activity is deficient.
DNA polymerase beta deficiency. As reviewed by Sobol [71], the base excision repair (BER)
pathway is used to repair many DNA damages including depurinated and depyrimidinated
bases (abasic sites), deaminated cytosine or 5-methylcytosine, and oxidation products such as
8-OH-dG, thymine glycol and lipid peroxidation products. Once the base lesion is removed
by one of 11 DNA glycosylases and the abasic site is hydrolysed by APE1 endonuclease, DNA
polymerse beta (POLB) is recruited to the lesion and carries out two functions: (1) removal of
the sugar-phosphate residue that remains after APE1 cleaves the DNA backbone and (2)
addition of the new nucleotide(s) to replace the one(s) removed during repair. A single
nucleotide polymorphism (SNP) in POLB (P242R) that acts at half the rate of wild-type POLB
occurs in 2.4% of individuals in certain human populations [72,73]. This P242R polymorphism
has reduced effectiveness in DNA repair and cells carrying the P242R polymorphism accu‐
mulate double-strand breaks at a higher rate than cells carrying the wild type allele [73]. The
population of humans examined and carrying the P242R SNP was not large enough to
determine whether this germ-line SNP increases the risk of cancer, so POLB is not listed in
Table 1. However, while germ-line mutations in POLB are not known to increase cancer risk,
the human POLB gene is mutated in 40% of colorectal tumors, though not in the field defects
surrounding the tumors [74]. Absence in the field defect but presence in the tumor suggests
that a mutation in POLB is a later step in progression to a tumor.
6. DNA damages give rise to mutations and epigenetic alterations
As described below, a substantial proportion of mutations are due to translesion synthesis past
otherwise un-repaired single-strand DNA damages, the most frequent endogenous DNA
damages in Table 2. However, while only a minority of endogenous DNA damages in the
average cell are double-strand breaks, this type of lesion appears to contribute substantially
to the mutation rate as well. As indicated by Vilenchik and Knudson [61], the doubling dose
for ionizing radiation (IR) induced double-strand breaks is similar to the doubling dose for
mutation and induction of carcinomas by IR. Thus, double-strand breaks likely lead frequently
to mutations. In addition, as further described below, some portion of the epigenetic alterations
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transmissible from one generation to the next (epimutations) appear to have arisen from
otherwise temporary alterations needed during steps in DNA repair.
7. Translesion synthesis past a DNA damage
Translesion synthesis (TLS) is a DNA damage tolerance process that allows the DNA replica‐
tion machinery to replicate past DNA lesions in the template strand. This allows replication
to be completed, rather than blocked (which may kill the cell or cause a translocation or other
chromosomal aberration) [75].
Humans have four translesion polymerases in the Y family of polymerases [REV1, Pol κ
(kappa), Pol η (eta), and Pol ι (iota)] and one in the B family of polymerases [Pol ζ (zeta)]. REV1
inserts cytosine opposite abasic sites in DNA (which may not be the correct base for that site)
and has a structural role in regulating Pol ζ. Pol ζ extends replication past distorted DNA pairs,
such as mismatched pairs of bases or bases with bulky DNA adducts. Pol η is a DNA poly‐
merase that efficiently replicates DNA templates containing thymine dimers. Pol ι utilizes
Hoogsteen base pairing for efficient and correct incorporation of cytosine opposite altered
purines, such as 8-oxoguanine, but also tends to incorporate guanine opposite thymine. Pol
κ is specialized in performing error-free bypass of bulky minor groove N2-deoxyguanine
adducts among other lesions, but is highly error-prone when replicating a normal portion of
a template [75].
The temporary tolerance of DNA damage during replication may allow DNA repair processes
to remove the damage later [76], and avoid immediate genome instability [77]. However,
translesion synthesis is less accurate than the replicative polymerases δ (delta) and ε (epsilon)
and tends to introduce mutations [75].
8. Mutation due to translesion synthesis
Deficiency in expression of a DNA repair gene allows excessive DNA damages to accumulate.
Some of the excess damages are likely processed by translesion synthesis, causing increased
mutation.
As one example, BRCA2 protein is normally active in the accurate homologous recombina‐
tional repair (HRR) pathway. Loss of both wild-type DNA repair gene BRCA2 alleles causes
rapid spontaneous acquisition of genome-wide somatic mutations in the replicating tissues of
mouse embryos. The mutations were measured in LacZ-plasmid transgenic reporter mouse
embryos, a system in which large genomic deletions, insertions and translocations can be
detected. The mutations found in BRCA2(-/-) mouse embryos are predominantly deletion/
rearrangement mutations consistent with mis-repair of DNA double-strand breaks arising
during DNA replication [78]. The proportion of deletion/rearrangement mutations (76%) in
the presence of BRCA2(-/-) is close to the proportion of deletion/rearrangement mutations (71%)
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among the much less frequent mutations found in the presence of the wild-type alleles
BRCA2(+/+). This finding suggests that the mode of error-prone translesion synthesis past any
un-repaired DNA damages is likely the same in BRCA2(-/-) and BRCA2(+/+) cells. In BRCA2(+/+)
cells, the accurate HRR pathway would take care of most of the relevant DNA damages, rather
than translesion synthesis.
Kunz et al. [79] summarized a large number of experiments in yeast, in which forward
mutations were measured (by sequence analyses of a few selected genes) in cells carrying either
wild-type alleles or one of 11 inactivated DNA repair genes. Their results indicated that DNA
repair deficient cells accumulate excess DNA damage that could then give rise to mutations
after error-prone translesion synthesis. The 11 inactivated DNA repair genes were distributed
among mismatch repair, nucleotide excision repair, base excision repair and homologous
recombinational repair genes. Deficiencies in DNA repair increased mutation frequencies by
factors between 2- and 130-fold, but most often by double digit-fold increases. Overall, the
authors concluded that 60% or more of single base pair substitutions and deletions are likely
caused by translesion synthesis.
Hegan et al.  [80] studied forward mutation in mice to determine the spontaneous muta‐
tion frequency in the presence of wild-type alleles or in the presence of knockout muta‐
tions in five individual mismatch repair genes and in pairs of double knockout mismatch
repair  genes.  They used two mutation reporter  genes  within chromosomally  integrated,
recoverable phage lambda shuttle vectors to measure mutation frequencies and to deter‐
mine the types of mutations present. The inactivated mismatch repair genes were in Pms2,
Mlh1, Msh2, Msh3 and Msh6. All mice with nullizygous mutations in these mismatch repair
genes had significantly increased mutation frequencies compared to wild-type mice with
both reporter genes tested. The highest two individual mutation frequencies were found in
mice defective for Mlh1 (>72-fold increase) and Msh2 (65-fold increase). The double knockout
mice had still higher frequencies of mutation than the single knockout mice. The greatest
increase found was with the Msh3-/-/Msh6-/-  double knockout mice that had more than a
100-fold increase in mutation frequency with one of the reporter genes compared to wild-
type mice. In these mismatch repair deficient mice, the majority of mutations found were
generally insertion and deletion mutations.
Stuart et al. [81] examined spontaneous mutation frequencies in a lacI transgene (in a Big Blue
mutation assay [82]) in either replicating tissues or in largely non-replicating tissues of mice.
If most mutations occur during translesion synthesis, then non-replicating brain tissue, which
has little or no synthesis once maturity is reached, would have little or no further mutation
accumulation. In mouse brain, after 6 months of age, there was no increase in mutation
frequency, even at 25 months of age. In bladders of mice, with replicating tissues, mutation
frequency increased with age, almost tripling between ages of 1.5 months and 12 months of
age. The authors concluded that the age related increases in spontaneous mutation frequencies
reflect endogenous DNA damages that were subsequently expressed as mutations following
DNA replication. This indicates that translesion synthesis is a major source of mutation in the
mouse.
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9. Mutation due to error prone repair of double-strand breaks
As described by Bindra et al. [83], non-homologous end-joining (NHEJ) and homologous
recombination repair (HRR) comprise the two major pathways by which double-strand breaks
(DSBs) are repaired in cells. NHEJ processes and re-ligates the exposed DNA termini of DSBs
without the use of significant homology, whereas HRR uses homologous DNA sequences as
a template for repair. HRR predominates in S-phase cells, when a sister chromatid is available
as a template for repair, and is a high-fidelity process. NHEJ is thought to be active throughout
the cell cycle, and it is more error-prone than HRR. NHEJ repair comprises both canonical
NHEJ and non-canonical pathways. The former pathway results in minimal processing of the
DSB during repair, whereas the latter pathway, with or without the use of sequence microho‐
mology for re-ligation, typically results in larger insertions or deletions. Mutagenic NHEJ
repair is a robust process, yielding percentages of mutated sites at the position of a DSB ranging
from 20 to 60%.
As pointed out by Vilenchik and Knudson [61], about 1% of single-strand DNA damages
escape repair and are not bypassed, and some of these become converted to double-strand
breaks. This may contribute to the impact of double-strand breaks in causing mutations and
carcinogenesis.
10. Epigenetic alterations occur due to DNA damage
Experiments have been conducted to determine the molecular steps by which epigenetic
alterations arise due to incomplete repair of DNA double-strand breaks. In one experiment
O’Hagan et al. [84] used a cell line that was stably transfected with a plasmid containing a
consensus I-SceI cut site inserted into a copy of the E-cad promoter. This promoter contained
a CpG island (where a cytosine nucleotide frequently occurs next to a guanine nucleotide in
the linear sequence of bases). The cytosines in these CpG islands are often hypermethylated,
causing epigenetic repression of the associated genes. Such hypermethylations occur in
multiple human tumor types. The investigators induced a defined double-strand break in the
E-cadherin CpG island, which was not currently hypermethylated. After the onset of repair of
the break, they observed the expected recruitment to the site of damage of key proteins
involved in establishing and maintaining transcriptional repression, to allow repair of the
break. These proteins included SIRT1, EZH2, DNMT1, and DNMT3B. Furthermore, silencing
histone modifications appeared including hypoacetyl H4K16, H3K9me2 and me3, and
H3K27me3. In most cells selected after the DNA break, DNA repair occurred faithfully with
preservation of activity of the promoter, and removal of the silencing factors. However, a small
percentage of the plated cells demonstrated induction of heritable silencing. The chromatin
around the break site in such a silent clone was enriched for most of the silencing chromatin
proteins and histone marks, and the region had increased DNA methylation in the CpG island
of the promoter. Their data suggested that repair of a DNA break can occasionally cause
heritable silencing of a CpG island-containing promoter by recruitment of proteins involved
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in silencing and leading to aberrant CpG island DNA methylation,. Such CpG island methyl‐
ation is frequently associated with tight gene silencing in cancer.
In a second experiment showing that epigenetic alterations arise as a consequence of DNA
damage, Morano et al. [85] studied a system in which recombination between partial dupli‐
cations of a chromosomal Green Fluorescent Protein (GFP) gene is initiated by a specific
double-strand break (DSB) in one copy. The unique DSB is generated by cleavage with the
meganuclease I-SceI, which does not otherwise cleave the eukaryotic genome. The DSB is
repeatedly formed and repaired, until the I-SceI site is lost by homologous or nonhomologous
repair or depletion of the I-SceI enzyme. Recombination products can be detected by direct
analysis of the DNA flanking the DSB or by the appearance of functional GFP (green fluores‐
cent cells). Two cell types were generated after recombination: clones expressing high levels
of GFP and clones expressing low levels of GFP, referred to as H and L clones, respectively.
Relative to the parental gene, the repaired GFP gene was hypomethylated in H clones and
hypermethylated in L clones. The altered methylation pattern was largely restricted to a
segment just 3’ to the DSB. Hypermethylation of this tract significantly reduced transcription,
although it is 2000 base pairs distant from the strong cytomegalovirus (CMV) promoter that
drives GFP expression. The ratio between L (hypermethylated) and H (hypomethylated)
clones was 1:2 or 1:4, depending on the insertion site of the GFP reporter. These experiments
were performed in mouse embryonic (ES) or human cancer (Hela) cells. HRR-induced
methylation was dependent on DNA methyltransferase I (DNMT1). These data, taken
together, argue for a cause-effect relationship between DNA damage-repair and altered DNA
methylation.
The main function of the proteins in the base excision repair (BER) pathway is to repair DNA
single-strand breaks and deamination, oxidation, and alkylation-induced DNA base damage.
Li et al. [86] reviewed recent studies indicating that one or more BER proteins may also
participate in epigenetic alterations involving DNA methylation or reactions coupled to
histone modification. Franchini et al. [87] showed that DNA demethylation can be mediated
by BER and other DNA repair pathways requiring processive DNA polymerases. Still another
form of epigenetic silencing may occur during DNA repair. The enzyme PARP1 [poly(ADP)-
ribose polymerase 1] and its product poly(ADP)-ribose (PAR) accumulate at sites of DNA
damage as intermediates of a repair process [88]. This, in turn, directs recruitment and
activation of the chromatin remodeling protein ALC1 that may cause nucleosome remodeling
[89]. Nucleosome remodeling has been found to cause, for instance, epigenetic silencing of
DNA repair gene MLH1 [90]. Thus, DNA damages needing repair can cause epigenetic
alterations by a number of different mechanisms.
11. Other causes of epigenetic alterations
Heavy metals and other environmental chemicals cause many epigenetic alterations, including
DNA methylation, histone modifications and miRNA alterations [92]. DNA damage itself
causes programmed changes in non-coding RNAs, and a large number of miRNAs are
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transcriptionally induced upon DNA damage [93]. However, it is not clear what proportion
of these alterations are reversed or are retained as epimutations after the external sources of
damage are removed upon repair of the DNA damages [94].
Mutations in isocitrate dehydrogenase 1 (IDH1) and 2 (IDH2) are frequent in a number of cancers
and they can cause epigenetic alterations. As reviewed by Wang et al. [95], IDH1 and IDH2
mutations represent the most frequently mutated metabolic genes in human cancer, mutated
in more than 75% of low grade gliomas and secondary glioblastoma multiforme (GBM), 20%
of acute myeloid leukemias (AML), 56% of chondrosarcomas, over 80% of Ollier disease and
Maffucci syndrome, and 10% of melanomas. The IDH1 and IDH2 mutations that give rise to
epimutations usually occur in the hotspot codons Arg132 of IDH1, or the analogous codon
Arg172 of IDH2. These mutations allow accumulation of the metabolic intermediate 2-
hydroxyglutarate (2-HG), and 2-HG inhibits the activity of alpha ketoglutarate (α-KG)
dependent dioxygenases, including α-KG-dependent histone demethylases and the TET
family of 5-methylcytosine hydroxylases. Wang et al. [95] found that histone H3K79 dimethy‐
lation levels were significantly elevated in cholangiocarcinoma samples that harbored IDH1
or IDH2 mutations (80.8%) compared to tumors with wild-type IDH1 and IDH2 (45.0%). In
addition, they surveyed over 462,000 CpG sites in CpG islands, CpG shores and intragenic
regions, and found that 2,309 genes had significantly increased methylation in the presence of
Figure 1. Cut open gross specimen of proximal human colon showing multiple tumors [91]
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IDH1 or IDH2 mutations. In particular, Sanson et al. [96] found that methylation of the DNA
repair gene MGMT was associated with IDH1 mutation, since 81.3% of IDH1-mutated tumors
were MGMT methylated compared with 58.3% methylated in IDH1 non-mutated tumors.
Figure 2. Expression of three DNA repair proteins, KU86, ERCC1 and PMS2, at locations sampled along the 20 cm
length of a colon resection that had a cancer at the indicated location. [98]
12. Long-term epigenetic repression of DNA repair genes in progression to
cancer
A DNA repair gene that is epigenetically silenced or whose expression is reduced would not
likely confer any selective advantage upon a stem cell. However, reduced or absent expression
of a DNA repair gene would cause increased rates of mutation, and one or more of the mutated
genes could cause the cell to have a selective advantage. The defective DNA repair gene could
then be carried along as a selectively neutral or only slightly deleterious passenger (hitch-hiker)
gene when there is selective expansion of the mutated stem cell. The continued presence of a
DNA repair gene that is epigenetically silenced or has reduced expression would continue to
generate further mutations and epigenetic alterations.
The spread of a clone of cells with a selective advantage, but carrying along a gene with
epigenetically reduced expression of a DNA repair protein would be expected to generate a
field defect, from which smaller clones with still further selective advantage would arise. This
is consistent with the finding of field defects in colonic resections, that have both a cancer and
multiple small polyps, such as the one shown in Figure 1.
The protein expressions of three DNA repair genes within a 20 cm colon resection were
evaluated at six different locations within the resection (Figure 2) [97]. A colon resection, on
its inner epithelial surface, has a layer of epithelial crypts (microscopic, test tube like indenta‐
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tions about 100 cells deep), with 100 crypts per square millimeter. Each crypt is a clone of about
5,000 cells all generated by the 10 stem cells at the base of the crypt. One of the DNA repair
proteins, KU86, was only deficient infrequently, with the deficiencies occurring in small
patches (up to three crypts). These KU86 defects are not likely important in progression to
colon cancer. However, two evaluated DNA repair proteins, ERCC1 and PMS2, were often
deficient in patches of tens to hundreds of adjacent crypts at each of the locations evaluated
(see Nguyen et al. [99] at minutes 18 to 24 of a 28 minute video of crypts immunostained for
ERCC1 or PMS2).
Overall, ERCC1 was deficient in 100% of 49 colon cancers evaluated, and in 40% of the crypts
within 10 cm on either side of the cancer. PMS2 was deficient in 88% of the 49 cancers and in
50% of the crypts within 10 cm of the cancer. As reported by Facista et al. [97], the pattern of
expression of ERCC1 in the crypts within 10 cm of a colon cancer indicated that when the
ERCC1 protein was deficient, this deficiency was due to an epigenetic reduction in expression
of the ERCC1 gene. When the PMS2 protein is deficient, it is usually due to the epigenetic
repression of its pairing partner, MLH1, and the instabilty of PMS2 in the absence of MLH1
[100]. In the study of Facista et al. [97], ERCC1 and PMS2 were also deficient in all 10 tubulo‐
villous adenomas evaluated (precursors to colonic adenocarcinomas). Thus ERCC1 and PMS2
are deficient at early times (in the field defect), at intermediate times (tubulovillus polyps), and
late times (within cancer) during progression to colon cancer. Another DNA repair protein,
XPF, was deficient in 55% of the cancers, as well [97]. The majority of cancers were simulta‐
neously deficient for ERCC1, PMS2 and XPF.
Deficiencies in multiple DNA repair genes were also observed in gastric cancers. Kitajima et
al. [101] evaluated MGMT, MLH1 and MSH2 and found that synchronous losses of MGMT
and MLH1 increase during progression and stage of differentiated-type cancers. In un-
differentiated-type gastric cancers, the frequency of MGMT deficiency increased from early to
late stages of the cancer, while frequencies of MLH1 and MSH2 deficiencies were between 48%
and 74% at both early and late stages. Thus, in un-differentiated-type gastric cancers, MLH1
or MSH2 deficiency, if it is present, is an early step, while MGMT deficiency is often a later
step in progression of this cancer.
Farkas et al. [102] evaluated 160 genes in 12 paired colorectal tumors and adjacent histologically
normal mucosal tissues for differential promoter methylation. They found aberrant methyla‐
tion in 23 genes, including six DNA repair genes. These DNA repair genes (with DNA repair
pathways indicated) were NEIL1 (base excision repair), NEIL3 (base excision repair),
DCLRE1C (non-homologous end joining), NHEJ1 (non-homologous end joining), GTF2H5
(nucleotide excision repair), and CCNH (nucleotide excision repair).
Jiang et al. [103] evaluated the mRNA expression of 27 DNA repair genes in 40 astrocytomas
compared to normal brain tissues from non-astrocytoma individuals. They found that 13 DNA
repair genes, MGMT, NTHL1, OGG1, SMUG1, ERCC1, ERCC2, ERCC3, ERCC4, MLH1, MLH3,
RAD50, XRCC4 and XRCC5 were all significantly down-regulated in all three grades (II, III
and IV) of astrocytomas. The deficiencies of these 13 genes in lower grade as well as in higher
grade astrocytomas indicated that they may be important in early as well as in later stages of
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astrocytoma. For 8 DNA repair genes, ERCC3, ERCC4, MLH3, MRE11A, NTHL1, RAD50,
XRCC4 and XRCC5, decreased expression was significantly associated with a poor prognosis.
Based on the examples above, decreased expression of multiple DNA repair genes is likely to
occur in many types of neoplasia. This should result in increased mutation frequency in those
neoplastic lesions. Most new mutations are expected to be deleterious to the cells in which they
arise, and thus would cause negative selection of those cells. This expectation is consistent with
the observations of Hofstad et al. [104] who showed that when a colonic polyp was identified
during a colonoscopy and followed but not removed, between 11% and 46% of those polyps
smaller than 5 mm diameter were not detectable in the succeeding one to three years. For
polyps between 5 and 9 mm in diameter, between 4 and 24% became undetectable in the
succeeding one to three years. Of the remaining 68 polyps that were followed for three years,
35% decreased in diameter, 25% remained the same size and 40% increased in diameter. The
data of Hofstad et al. [104] are also consistent with statistics showing more frequent occurrence
of adenomas during colonoscopy and autopsy compared to the frequency of colon cancer,
indicating there must be a significant regression rate for adenomas [105].
When infrequent positively selected mutations arise in a cell, this can provide the cell with a
competitive advantage that promotes its preferentiail clonal proliferation, leading to cancer.
The continued presence of epigenetically repressed DNA repair genes, carried along as
passengers in the development of cancers, also predicts that cancers will contain heterogene‐
ous genotypes (multiple subclones). For instance, in one primary renal carcinoma with
multiple metastases, 101 non-synonymous point mutations and 32 indels (insertions and
deletions) were identified [106]. Five mutations were not validated and excluded from the
study. Of the remaining 128 mutations, 40 were “ubiquitous” and present in each region of
the tumor sampled. There were 59 “shared” mutations, present in several but not all regions,
and 29 “private” mutations, unique to a specific region evaluated. The authors constructed a
phylogenetic tree and concluded that the evolution in the tumor and its metastases was
branching, and not linear. Similar results were found in a further three tumors evaluated in
their study. Every tumor had spatially separated heterogeneous somatic mutations and
chromosomal imbalances leading to phenotypic intratumor diversity.
13. Epigenetic repression of DNA repair genes in field defects in
progression to cancer
As described in detail by Rubin [107], field defects are of central importance in progression to
cancer. While the great majority of studies in cancer research has been done on well-defined
tumors formed in vivo, evidence indicates that more than 80% of the somatic mutations found
in microsatellite instability (MSI) (mutator phenotype) human colorectal tumors occur before
the onset of terminal clonal expansion. This evidence included the finding that adenomas were
phylogenetically nearly as old as cancers. The origin of field defects was described by Braa‐
khuis et al. [108] as follows. They postulated that a stem cell acquires one (or more) genetic
alterations and forms a patch with genetically altered daughter cells. As a result of these and
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subsequent genetic alterations the stem cell escapes normal growth control, gains a growth
advantage, and develops into an expanding clone. The lesion, gradually becoming a field,
laterally displaces the normal epithelium. The enhanced proliferative capacity of a genetically
altered clonal unit is the driving force of the process. As the lesion becomes still larger,
additional genetic hits give rise to various subclones within the field. Different clones diverge
at a certain time point with respect to genetic alterations but share a common clonal origin.
The presence of a relatively large number of genetically altered stem cells in a field is a “ticking
time bomb,” and as a result of the process of clonal divergence and selection, eventually a
subclone evolves into invasive cancer.
Cancer Gene Frequency in
Cancer
Frequency in Field
Defect
Ref.
Colorectal MGMT 46% 34% [12]
Colorectal MGMT 47% 11% [109]
Colorectal MGMT with MSI* 70% 60% [110]
Colorectal MSH2 13% 5% [109]
Colorectal MBD4 frequent frequent [111]
Colorectal ERCC1 100% 40% [97]
Colorectal PMS2 88% 50% [97]
Colorectal XPF 55% 40% [97]
Colorectal WRN 29% 13% [112]
Head and Neck MGMT 54% 38% [113]
Head and Neck MLH1 33% 25% [114]
Head and Neck MLH1 31% 20% [115]
Lung NSCLC ATM 69% 59% [116]
Lung NSCLC MLH1 69% 72% [116]
Stomach MGMT 88% 78% [117]
Stomach MLH1 73% 20% [118]
Esophagus MLH1 77%-100% 23%-79% [119]
*MSI indicates microsatellite instability
Table 3. Frequency of finding epigenetic reductions in protein expression of DNA repair genes in sporadic cancers and
in adjacent field defects
Epigenetic reductions in protein expression of DNA repair genes are frequent in cancers (Table
3). For any particular type of cancer, an epigenetic reduction in expression of a specific DNA
repair gene, such as an epigenetic reduction of MGMT in colorectal cancer, may be common.
In cases where a specific epigenetic reduction of expression of a DNA repair gene occurs in a
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cancer, it is also likely to be evident in the field defect surrounding the cancer (Table 3). The
lower frequency in the surrounding field defect that is often found (Table 3) likely reflects the
process whereby the expanding clone is laterally displacing the normal epithelium. This
displacement may be only partial. Thus, areas with the DNA repair deficiency would be
present at a lower frequency in the field defect than in the cancer. In the cancer, the cells
carrying the DNA repair deficiency are members of a founding clone. Thus, the DNA repair
defect, along with other accumulated mutations and epigenetic alterations, would be seen in
the cancer at a relatively higher frequency than in the surrounding field defect.
14. Examples of epigenetic repression of DNA repair genes, due to
alterations in CpG island methylation, in various cancers
Table 4, below, gives examples of reports of DNA repair genes repressed by CpG island
hypermethylation (or with increased expression due to CpG hypomethylation) in 17 different
cancers (this is only a partial list). Twenty different DNA repair genes (all listed among the 169
DNA repair and DNA damage response genes previously identified [62]) were often hyper-
(or sometimes hypo-) methylated in one or more type of cancer. Such alterations in methylation
of promoter regions of DNA repair genes can cause deficient repair of DNA damages. Thus,
hyper- (or hypo-) methylations of DNA repair genes are frequently important factors respon‐
sible for lack of appropriate repair of DNA damages. Faulty DNA repair leads to increased
mutation and epigenetic alteration, central to progression to cancer.
MGMT is one of the DNA repair genes often evaluated for hypermethylation. Of the cancers
listed in Table 4, nine were reported to have some frequency of hypermethylation of MGMT.
Hypermethylation of MGMT was particularly frequent in bladder cancer (93%), stomach
(88%), thyroid (74%), colorectal (40-90%) and brain (50%).
Other DNA repair genes with high frequencies of hypermethylation (in particular cancers)
were LIG4 (colorectal 82%), P53 (brain 60-74%), NEIL1 [head and neck 62% and non-small cell
lung cancer (NSCLC) 42%], ATM (NSCLC 47%), MLH1 (NSCLC squamous cell carcinoma 48%)
and FANCB (head and neck 46%). The DNA repair genes LIG4, P53, NEIL1 and FANCB were
frequently not evaluated for hypermethylation in other particular types of cancers, and could
be of importance in such cancers as well.
15. DNA repair gene ERCC1 expression likely can be repressed by multiple
processes
A number of the DNA repair genes with reduced expression due to CpG island hypermethy‐
lation are also epigenetically repressed by other means. Many protein coding genes are
repressed by microRNAs. MicroRNAs (miRNAs) are small noncoding endogenously pro‐
duced RNAs that play key roles in controlling the expression of many cellular proteins. Once
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they are recruited and incorporated into a ribonucleoprotein complex, they can target specific
messenger RNAs (mRNAs) in a miRNA sequence-dependent process and interfere with the
translation into proteins of the targeted mRNAs via several mechanisms (see detailed review
by Lages et al. [120]).
Almost one third of miRNAs active in normal mammary cells were found to contain hyper‐
methylated DNA regions in breast cancer cells [121]. This includes, for instance, microRNAs
let-7a-3/let-7b.
As indicated by Motoyama et al., [122] the let-7a miRNA normally represses the HMGA2 gene,
and in normal adult tissues, almost no HMGA2 protein is present. In breast cancers, for
instance, the promoter region controlling let-7a-3/let-7b microRNA is frequently repressed by
hypermethylation [121]. Reduction or absence of let-7a microRNA allows high expression of
the HMGA2 protein. HMGA proteins are characterized by three DNA-binding domains, called
AT-hooks, and an acidic carboxy-terminal tail. HMGA proteins are chromatin architectural
transcription factors that both positively and negatively regulate the transcription of a variety
of genes. They do not display direct transcriptional activation capacity, but regulate gene
expression by changing local DNA conformation. Regulation is achieved by binding to AT-
rich regions in the DNA and/or direct interaction with several transcription factors [123].
HMGA2 targets and modifies the chromatin architecture at the ERCC1 gene, reducing its
expression [124]. The lack of let-7a miRNA repression of HMGA2 could occur through
translocation of HMGA2, disrupting the 3’UTR of HMGA2 which is the target of let-7a miRNA
(shown in an artificial construct), and this can lead to an oncogenic transformation [125].
However, the promoter controlling let-7a miRNA also can be strongly regulated by hyperme‐
thylation in intact cells. When human lung cells are exposed to cigarette smoke condensation,
the promoter region controlling let-7a becomes highly hypermethylated [126]. While only 38%
of colorectal cancers have CpG island methylation of the ERCC1 promoter (Table 4), Facista et
al. [97] found that 100% of colon cancers have significantly reduced levels of ERRC1 protein
expression. In the 49 cancers examined, ERCC1 generally varied from 0% to 45% of the level
of ERCC1 expression of neoplasm-free individuals. It is likely that hypermethylated promoter
for let-7a microRNA/hyperexpressed HMGA2 or other epigenetic mechanism(s) reduces
protein expression of ERCC1 in colorectal cancers in addition to the 38% of colorectal cancers
in which the ERCC1 gene is directly hypermethylated.
16. DNA repair gene BRCA1 expression likely can be repressed by multiple
processes
BRCA1 expression is reduced or undetectable in the majority of high-grade, ductal carcinomas
[127]. Among 32 breast cancers examined, none had a sporadic mutation in the BRCA1 gene
[128]. The frequency of BRCA1 promoter hypermethylation in breast cancer is only 13-16%
[129,130] (see Table 4). However, miR-182 targets BRCA1 [131] and the promoter controlling
expression of miR-182 is hypomethylated (would have increased expression) in cancers, as
indicated by Shnekenburger and Diederich [132]. Tang et al. [133] showed that transcription
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of miR-182 is repressed when the promoter controlling its transcription is methylated so that
miR-182 is clearly an epigenetically regulated miRNA. Moskwa et al. [131] showed that basal-
like ER-negative breast cancer cell lines had relatively low levels of BRCA1 protein and in five
of the six ER negative cell lines there was inverse correlation of BRCA1 protein and miR-182
expression. Thus epigenetically increased expression of miR-182 appears to be implicated in
reducing BRCA1 protein expression in breast cancer.
There is a further potential epigenetic mechanism for repressing BRCA1 in breast cancers.
miR-34b is repressed by methylation of its promoter [134]. A target of miR-34b is HMGA1 [135].
When miR-34b is repressed, expression of HMGA1 is increased [136]. HMGA1 protein appears
to target BRCA1. Baldaserre et al. [136] found an inverse correlation between HMGA1 and
BRCA1 mRNA and protein expression in human mammary carcinoma cell lines and tissues.
Thus epigenetically methylated promoter for transcription of miR-34b/increased HMGA1 may
be instrumental in reducing BRCA1 protein expression in breast cancer. It is not clear whether
increased miR-182 (see paragraph above) or decreased miR-34b is the more important factor
in repressing BRCA1 in breast cancers.
17. DNA repair gene MGMT expression is repressed by multiple processes
In the most common form of brain cancer, glioblastoma, the DNA repair gene MGMT is
epigenetically methylated in 29% [137] to 66% [138] of tumors, thereby reducing protein
expression of MGMT. However, for 28% of glioblastomas, the MGMT protein is deficient but
the MGMT promoter is not methylated [138]. Zhang et al. [137] found, in the glioblastomas
without methylated MGMT promoters, that the level of microRNA miR-181d is inversely
correlated with protein expression of MGMT and that the direct target of miR-181d is the
MGMT mRNA 3’ UTR (the three prime untranslated region of MGMT mRNA). miR-181d
normally occurs at very low levels in the brain [139]. It is not clear whether miR-181d is
epigenetically up-regulated, when it occurs at increased levels in the brain. Thus it is not clear
if this second process of reducing MGMT expression in progression to glioblastoma is an
epigenetic one.
Cancer Gene
Frequency of hyper-
(or hypo-) methylation in
cancer
Ref.
Bladder MGMT 93% [140]
Bone
Chondrosarcoma WRN 33% [141]
Osteosarcoma MGMT 24% [142]
Osteosarcoma WRN 11% [141]
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Cancer Gene
Frequency of hyper-
(or hypo-) methylation in
cancer
Ref.
Brain (glioma) P53 60%-74% [143]
MGMT 50% [144]
ERCC1 38% [145]
Breast
WRN 17% [141]
BRCA1 13%-16% [129, 130]
P53 12% [145]
FEN1 Frequent (hypo-) [146]
Colorectal
LIG4 82% [147]
MGMT 40%-90% [12-16]
ERCC1 38% [148]
WRN 29%-38% [112, 141]
MLH1 9%-10% [100, 149]
FEN1 Frequent (hypo-) [146]
MBD4 Frequent [150]
Hematological
Non-Hodgkin
lymphoma WRN 24% [141]
Acute
lymphblasstic
leukemia
WRN 10% [141]
Acute
myeloblastic
leukemia
WRN 5% [141]
Head and Neck
APEX2 100% hypo- [151]
TREX2 79% hypo- [151]
NEIL1 62% [151]
MSH4 60% hypo- [151]
Epigenetic Reduction of DNA Repair in Progression to Cancer
http://dx.doi.org/10.5772/60022
191
Cancer Gene
Frequency of hyper-
(or hypo-) methylation in
cancer
Ref.
MGMT 25%-57% [151- 153]
FANCB 46% [151]
ATM 25% [154]
MLH1 33% [155]
MLH1 4% [152]
Kidney
MGMT 9% [156]
FEN1 Frequent (hypo-) [146]
Lung
NSCLC NEIL1 42% [157]
NSCLC WRN 38% [141]
NSCLC MGMT 13%-64% [157- 159]
NSCLC ATM 47% [116]
NSCLC Squamous
cell carcinoma MLH1 48% [160]
NSCLC
Adenocarcinoma MSH2 42% [160]
BRCA2 42% [161]
BRCA1 30% [161]
XRCC5 20% [161]
FEN1 Frequent (hypo-) [146]
Ovarian P53 52% [162]
MSH2 52% [163]
MLH1 30% [163]
MBD4 Frequent(hyper-) [150]
Prostate WRN 20% [141]
Stomach MGMT 88% [111]
MLH1 73% [118]
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Cancer Gene
Frequency of hyper-
(or hypo-) methylation in
cancer
Ref.
WRN 24%-25% [141, 164]
FEN1 Frequent (hypo-) [146]
Thyroid MGMT 74% [165]
MLH1 21% [166]
PCNA 13% [166]
WRN 13% [141]
OGG1 5% [166]
Uterus MLH1 14% [167]
FEN1 Frequent (hypo-) [146]
Table 4. CpG island hyper- (and hypo-) methylation in DNA repair genes in cancers
18. DNA repair proteins and miRNAs
A number of investigators have tried to relate alteration in DNA repair gene expression to
altered level of miRNA expression. For instance, Wouters et al. [168], using “in silico” computer
programs (Targetscan and Mirbase), listed 74 DNA repair or DNA Damage Response (DDR)
genes and, for each of these genes, listed between 1 and 19 “conserved” miRNAs that were
predicted to repress the particular genes. They defined “conserved” miRNAs as miRNAs
found in at least five mammalian species. For the purposes of this review, in which we are
concerned with epigenetic alterations that control DNA repair, about half of the miRNAs they
found “in silico” would not be of interest because they were inducible by UV irradiation, and
thus may have been largely controlled by a transient transcriptional regulatory change rather
than epigenetically.
More recently, focusing on the DNA repair gene MGMT, Kushiwaha et al. [169] used five
different “in silico” computer programs to predict which of 885 miRNAs would repress the
DNA repair protein MGMT. Kushiwaha et al. [169] also transfected each of the 885 miRNAs
into a glioblastoma cell line where the cell line had a high original expression of MGMT. They
found 103 of the tested miRNAs did reduce MGMT expression in vitro by more than 50%
without causing high cytotoxicity. However, the correspondence of predicted “in silico”
interactions of the miRNAs with experimentally found interactions was rather low, 20% at
best, indicating that “in silico” predictions often are not biologically relevant. Of the 103
miRNAs that reduced expression of MGMT, 15 had an inverse correlation with MGMT
expression in vivo in promoter-unmethylated glioblastoma tissue specimens. These 15
miRNAs included miR-181d that Zhang et al. [137] had previously shown to be inversely
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correlated with MGMT in glioblastomas. Kushiwaha et al. then focused further on one of the
15 miRNAs, miR-603, which strongly suppressed MGMT. In 23 glioblastoma cell lines, miR-603
was expressed at levels that varied by about 20 fold. It is not known whether the different
expression levels were due to epigenetic control. They then determined that miR-603 sup‐
pressed MGMT by direct interaction with the 3’UTR region of MGMT mRNA, using mRNA-
biotinylated miRNA complex pull down reactions with streptavidin coated magnetic beads.
They were able to further show that miR-603 could cooperate with miR-181d to completely
silence MGMT expression by jointly binding to nearby locations on the MGMT mRNA 3’UTR.
These miRNA controls of expression of a DNA repair enzyme are illustrative of how miRNAs
may interact with mRNAs to control their expression. In the experiments discussed in this
paragraph, the miRNAs appear to be important in reducing expression of a DNA repair
enzyme in progression to glioblastoma, but the extent to which epigenetic mechanisms are
employed to control the level of the miRNAs is unclear.
Both Tessitore et al. [170] and Vincent et al. [171] listed about 20 miRNAs that are altered in
cancers and that also control expression of DNA repair genes. The lists are not entirely
overlapping. However, they do not indicate how these miRNAs are deregulated.
Deregulation of miRNA expression in cancers has been found to occur by a number of non-
epigenetic mechanisms [120, 172]. One mechanism includes alterations in genomic miRNA
copy numbers and location. Some of these are deletions that include the miRNA clusters 15a/
16-1 or let-7g/mir-135-1,or else amplification or translocation of the mir-17-92 cluster. In some
cancers miRNAs were deregulated because of defects in the biogenesis mechanism (the process
of creating miRNAs, which has a number of steps). Some cancers have deregulated miRNAs
due to single nucleotide polymorphisms (SNPs) in the genes coding for the miRNAs, or SNPs
in the target gene area to which the miRNA is targeted. Some miRNAs, that target DNA repair
genes, are regulated by oncogenes. For instance ATM is down-regulated by miR-421, but
miR-421 is regulated by N-Myc [173]. Thus, not all deregulation of DNA repair genes or DDR
genes by miRNAs is due to epigenetic alteration affecting expression of the miRNAs.
19. Examples of epigenetic repression of DNA repair genes, due to
alterations in methylation of promoters of miRNAs in various cancers
Table 5 lists nine miRNAs that have three characteristics. (1) Their expression is epigenetically
controlled by the methylation level of the promoter region coding for the miRNA, (2) they
control expression of DNA repair genes and (3) their level of expression was frequently
epigenetically altered in one or more types of cancer. This list is not exhaustive. Many of the
30 miRNAs listed by Tessitore et al. [170] or Vincent et al. [171] might also meet these criteria
upon further examination. Four of the miRNAs on this list are not noted by Tessitore et al.
[170] or Vincent et al. [171]. Studies of most of these epigenetically controlled miRNAs have
not noted the frequencies with which they occur in cancers. This is a very recent area of
research, and seems to be less systematic, at this point, than studies of hypermethylation of
promoter regions of DNA repair genes.
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DNA repair gene
targets
Cancers affected
(frequency if
measured)
Refs indicating
epigenetic control
of miRNA
Refs
indicating
target gene(s)
of miRNAs
Refs indicating
cancer type
affected
MiR-103
MiR-107 RAD51, RAD51D
Osteosarcoma, lung,
endometrial, stomach [174] [175] [175]
MiR-34c
UNG
(uracil DNA
glycosylase)
Gastric (70%)
Field defect gastric
(27%)
Colon (98%)
Field defect colon
(60%)
Chronic lymphocytic
leukemia (18%)
Small-cell lung cancer
(67%)
NSCLC (26%)
[176] [177] [49, 176, 178, 179]
MiR-124 KU70 Colon [180] [181] [180]
MiR-155
RAD51
MLH1
MSH2
MSH6
Breast
Colon [121, 182] [18, 183] [18, 121]
Let-7a repression
increases HMGA2;
HMGA2 alters
chromatin
architecture of and
represses ERCC1)
ERCC1
(Colon)
Anaplastic
astrocytoma
[121] [184, 185] [185]
Let-7b repression
increases HMGA1;
HMGA1 targets P53
P53 ProstateColon [121] [186, 187] [186, 187]
miR-34b repression
increases HMGA1;
HMGA1 targets
BRCA1
BRCA1 Breast [134] [135, 136] [136]
MiR-182 BRCA1 Breast [133] [131] [131]
Table 5. Epigenetically controlled miRNAs, altered in cancers, that target DNA repair genes
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20. Whole genome sequencing indicates a high level of mutagenesis in
cancers
Almost 3,000 pairs of tumor/normal tissues were analyzed for mutations by whole exome
sequencing (WES) (sequencing the protein coding parts of whole genomes) and more than a
hundred pairs of tumor/normal tissues were analyzed for mutations by whole genome
sequencing (WGS) by Lawrence et al. [188]. Median mutation frequencies for 27 different types
of cancer were found to vary by 1,000-fold. When there was a particular median mutation
frequency for a type of cancer, the scatter of values (in individual cancers) for that type of
cancer, above and below that median value, also varied by as much as 1,000-fold. Some
mutation rates, given as numerical values of median numbers of mutations per megabase in
a review of the literature by Tuna and Amos [189], are shown in Table 6, and the values were
also converted to mutations per whole diploid genome in the table.
The mutation frequency in the whole genome (not just the protein coding regions) between
generations for humans (parent to child) is about 30 - 70 new mutations per generation
[190-192]. For protein coding regions of the genome in individuals without cancer, Keightley
[193] estimated there would be 0.35 mutations per parent to child generation. Whole genome
sequencing was also performed in blood cells for a pair of monozygotic (identical twin) 100
year old centenarians [194]. Only 8 somatic differences were found between the twins, though
somatic variation occurring in less than 20% of blood cells would be undetected.
As seen in Table 6, tumors have a substantially higher frequency of mutations than the number
of new mutations per generation in individuals without cancer. Also notable in Table 6, tumors
with more exposure to DNA damage (lung cancers of smokers, and melanomas in individuals
with high UV exposure) had higher mutation frequencies than the comparable tumors for
patients with less exposure to DNA damage (lung cancers of non-smokers and melanomas of
individuals without high UV exposure).
The information from whole exome sequencing and whole genome sequencing showed that
different spectrums of mutations occurred in different tissues [188, 195]. Lung cancers shared
a spectrum dominated by C->A mutations, presumably consistent with exposure to polycyclic
aromatic hydrocarbons in tobacco smoke. Melanomas had a spectrum with frequent C->T
mutations caused by misrepair of UV-induced covalent bonds between adjacent pyrimidines.
Jia et al. [195] found 3-5 independent mutational signatures in 9 major types of cancers,
indicating a range of 3-5 predominant mutational processes in different cancers. Lawrence et
al. [188] also found about a 2.9-fold difference in mutation frequency across the genome
depending on expression level of the genes. Genes with higher expression had a lower
mutation frequency, possibly due to the availability of extra transcription-coupled repair. Also
the mutation frequency of genes replicated early in a cell replication cycle was 2.9 fold lower
than that of genes replicated late in the cycle.
While the type of mutation spectrum depended on the most frequent DNA damages in a given
tissue, and there were about 5-fold differences in mutation frequency depending on whether
genes were frequently transcribed or in a DNA region replicated at early or late times in a
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replication cycle, the largest differences in mutation frequency were due to being in a tumor
tissue versus a normal tissue (Table 6). These large differences in mutation frequency may
frequently be due to whether one or more DNA repair genes are epigenetically reduced in
expression in the stem cells giving rise to the development of the cancer.
Parent/child per generation or cancer type Mutation rate per millionbases
Mutation rate per diploid
genome
Parent/child per generation 0.00000023 70
Medullablastoma 0.15-0.6 900-3,600
Acute
lymphocytic leukemia 0.3 1,800
Chronic
lymphocytic leukemia <1 <6,000
Prostate cancer 0.9 5,400
Multiple myeloma 2.9 17,400
Colorectal carcinoma ~5 ~30,000
Microsatellite stable (MSS) colon cancer 2.8 16,800
Microsatellite instable (MSI) colon cancer (mismatch DNA
repair deficient) 47 282,000
Hepatocellular carcinoma 4.2 25,200
Breast cancer 1.18-1.66 7,080-9,960
Lung cancer 17.7 106,200
Small cell lung cancer 7.4 44,400
Non-small cell lung cancer (smokers) 10.5 63,000
Non-small cell lung cancer (non-smokers) 0.6 3,600
Lung adenocarcinoma (smokers) 9.8 58,500
Lung adenocarcinoma
(non-smokers) 1.7 10,200
Melanoma ~30 ~180,000
Chronic UV-irradiation
induced melanoma 111 666,000
Non-UV-induced melanoma of hairless skin of extremities 3-14 18,000-84,000
Non-UV-induced melanoma of hair-bearing skin 5-55 30,000-330,000
Table 6. Mutation rates per million bases or per diploid genome
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21. Epigenetically reduced expression of DNA repair genes in DNA repair
pathways in cancers
Figure 3 indicates typical DNA damaging agents, some of the lesions they cause and the
pathways used to repair these lesions. Many of the genes active in these pathways are indicated
by their acronyms. The acronyms listed in red represent genes shown, in Tables 3, 4 and 5,
whose expression is frequently reduced due to epigenetic alterations in many types of cancers.
The major DNA repair pathways are base excision repair, nucleotide excision repair, homol‐
ogous recombinational repair, non-homologous end joining, mismatch repair and direct
reversal. Each of these repair pathways employs one or more DNA repair enzymes that are
frequently epigenetically reduced in expression in one or more types of cancer. This could be
a substantial source of the genomic instability that is characteristic of cancers.
Figure 3. DNA damaging agents, the lesions they produce and the repair pathways that deal with the DNA damages,
including acronyms for many of the genes in each of the pathways. Acronyms in red represent genes listed in Tables 3,
4 and 5 and indicate reduction of expression due to epigenetic alteration in one or more types of GI cancer [196].
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22. Conclusion
Deficiencies in DNA repair due to inherited germ-line mutations in DNA repair genes cause
increased risk of cancer. Such DNA repair gene mutations allow excess unrepaired DNA
damages to accumulate in somatic cells. Then either inaccurate translesion synthesis past the
un-repaired DNA damages or the error-prone DNA damage response of non-homologous end
joining can cause mutations. Erroneous or incomplete DNA repair may also cause epimuta‐
tions. In sporadic cancers, mutations in DNA repair genes are relatively rare. However, at least
25 DNA repair genes are often epigenetically altered and have reduced expression in sporadic
cancers and in the field defects that give rise to the cancers. Such epimutations in DNA repair
genes also likely lead to a further increase in mutations and epimutations, and these mutations
and epimutations can include both the driver mutations and the other epigenetic alterations
central to progression to cancer. Whole genome sequencing of many different types of cancers
show that between thousands to hundreds of thousands of mutations occur in various types
of cancers. The epimutations in DNA repair genes that occur early in progression to cancer,
are a likely source of the high level of genomic instability characteristic of cancers. Epigenetic
reduction of DNA repair appears to be a frequent early step, central to progression to cancer.
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